Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Fujifilm’s Meniscus Regenerative Therapy to Be Priced as Medical Device
Japan’s Central Social Insurance Medical Council (Chuikyo) on August 5 agreed to apply medical device pricing rules to Fujifilm Toyama Chemical’s regenerative medicine product Savyscus (autologous synovial mesenchymal stem cells) ahead of its NHI listing. Savyscus was approved in May…
To read the full story
Related Article
REGULATORY
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
- Fujifilm’s Meniscus Regenerative Therapy to Be Priced as Medical Device
August 6, 2026
- CEA Review Group Debates Draft Report, Eyes August 18 Wrap-Up
August 5, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…